The management of atrial fibrillation in heart failure
The development of atrial fibrillation (AF) can greatly complicate the course of heart failure (HF). Although recent trials have indicated the nonsuperiority of a rhythm control strategy in the general population with AF, this may not apply to patients with HF. We feel strongly that AF be treated aggressively in patients with HF, defaulting toward an initial rhythm control strategy, to avoid the hemodynamic detriment of irregular rapid ventricular response and the development of tachycardia-related myopathy. The index episode is treated with cardioversion and antiarrhythmic therapy. If significant benefit is demonstrated, the rhythm control strategy is maintained, to the point of catheter ablation for AF if necessary. If there is no change in cardiac performance or symptoms after cardioversion, strict rate control is enforced, to the point of atrioventricular node ablation and pacing if necessary.
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 2.Maisel WH, Stevenson LW: Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy. Am J Cardiol 2003, 91:2D-8D. This paper discusses the interaction between AF and HF, with emphasis on the pathophysiology between the two disease states.PubMedCrossRefGoogle Scholar
- 8.Dries DL, Exner DV, Gersh BJ, et al: Atrial fibrillation associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. J Am Coll Cardiol 1998, 32:695–703.PubMedCrossRefGoogle Scholar
- 9.Middlekauf HR, Stevenson WG, Stevenson LW: Prognostic significance of atrial fibrillation in advanced heart failure: a study of 390 patients. Circulation 1991, 84:40–48.Google Scholar
- 11.Nattel S, Shiroshita A, Cardin S, et al: Mechanisms for atrial remodeling and clinical relevance. Curr Opin Cardiol 2004, 20:21–25.Google Scholar
- 17.Fuster V, Rydén LE, Asinger RW, et al: ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: Executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol 2001, 38:1231–1265.PubMedCrossRefGoogle Scholar
- 21.Wyse DG, Waldo AL, DiMarco JP, et al: A comparison of rate control and rhythm control in patients with atrial fibrillation. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. N Engl J Med 2002, 347:1825–1833. A large prospective study comparing rate control to rhythm control in patients with AF. One of the landmark trials challenging the assumption that rate control is an inferior option.PubMedCrossRefGoogle Scholar
- 22.Rationale and design of a study assessing treatment strategies of atrial fibrillation in patients with heart failure: the Atrial Fibrillation and Congestive Heart Failure (AF-CHF) trial [no authors listed]. Am Heart J 2002, 144:597–607.Google Scholar
- 26.Deedwania PC, Singh BN, Ellenbogen K, et al: Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the Veterans Affairs Congestive Heart Failure Survival Trial of Antiarrhythmic Therapy (CHF-STAT). Circulation 1998, 98:2574–2579.PubMedGoogle Scholar
- 27.Singh S, Zoble RG, Yellen L, et al: Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the Symptomatic Atrial Fibrillation Investigative Research on Dofetilide (SAFIRE-D) Study. Circulation 2000, 102:2385–2390.PubMedGoogle Scholar
- 28.Pederson OD, Bagger H, Keller N, et al: Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish Investigations of Arrhythmia and Mortality ON Dofetilide (DIAMOND) Substudy. Circulation 2001, 104:292–296.Google Scholar